Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04875962 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
A Phase 1 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04875962 is a Phase 1 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 31 participants.
The verdict
NCT04875962, a Phase 1 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with Parkinson's Disease (PD).
Interventions
- DRUG Placebo
- DRUG UCB0599
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-05-06 |
| Est. Completion | 2020-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04875962
The ClinicalTrials.gov registry entry for NCT04875962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04875962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04875962 about?
NCT04875962 is a clinical study titled "A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)". The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with Parkinson's Disease (PD).
What is the current status of trial NCT04875962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2019-05-06. Estimated completion is 2020-02-19.
What interventions are being tested in trial NCT04875962?
The interventions under investigation include: Placebo (DRUG), UCB0599 (DRUG).
Who is sponsoring clinical trial NCT04875962?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.